FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Stem cell research & therapy2025; 16(1); 547; doi: 10.1186/s13287-025-04671-1

Generation of equine induced pluripotent stem cells from cells of embryonic, perinatal and adult tissues.

Abstract: Regenerative therapies are quickly expanding to application in equine patients because of their importance as sporting and companion animals. Furthermore, aligning with a One Health concept, veterinary medicine offers a unique platform for preclinical studies. While mesenchymal stem/stromal cells (MSCs) therapies are already used in treating horses, strategies involving induced pluripotent stem cells (iPSCs) are poorly developed. iPSCs present great potential for therapy and disease modelling, but their consistent generation in horses requires further investigation into the source of somatic cells and the reprogramming method and conditions. Methods: The reprogramming potential of equine cells from tissues of three developmental origins was compared: prenatal (embryo-derived MSCs, eMSCs), perinatal (cord blood-derived MSCs, CB-MSCs) and adult (articular chondrocytes, ACs). Two reprogramming methods (retroviral, lentiviral) and different culture conditions (serum/serum-free, feeder cells/feeder-free, with/without small molecules) were tested. Pluripotent gene expression was analyzed at different time-points to reveal transcriptomic changes associated with reprogramming. The generated equine iPSCs (eqiPSCs) were characterized by alkaline phosphatase (AP) staining, expression of pluripotent genes and proteins, three-germ layer differentiation (embryoid body) and karyotype. Results: Using a lentiviral vector with serum-free media and feeder cells resulted in the most favorable conditions for eqiPSCs reprogramming, but adding small molecules had a negative effect. Equine CB-MSCs and ACs were only partially reprogrammed and could not be efficiently expanded in culture. Only eMSCs generated putative eqiPSCs that met the cellular, molecular and functional criteria of pluripotent cells. Equine eMSCs showed higher proliferation and basal expression of pluripotent genes compared to CB-MSCs and ACs, and showed the highest upregulation of pluripotent genes along reprogramming. Conclusions: The developmental stage of the starting cell strongly influences their reprogramming potential in equine species. This has been suggested for human and other animal species, but direct comparison of equine cells from prenatal, perinatal and adult sources has not been reported before. Novel preliminary insight into the transcriptomic changes of different equine cell types during reprogramming, and on the effect of different culture conditions, can contribute improving the generation of eqiPSCs. While transgene-free methods are the goal, putative eqiPSCs are critical to enlarge our knowledge on animal iPSC biology.
© 2025. The Author(s).
Get Full Text
Publication Date: 2025-10-08 PubMed ID: 41063189PubMed Central: PMC12506261DOI: 10.1186/s13287-025-04671-1Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

Overview

  • This study explores the generation of induced pluripotent stem cells (iPSCs) from different equine tissue sources at various developmental stages, evaluating the best methods and conditions for efficient reprogramming.
  • The research aims to improve the development of equine iPSCs (eqiPSCs) for potential regenerative therapies, disease modeling, and preclinical veterinary applications.

Introduction and Background

  • Equine patients, valuable both as sporting and companion animals, are increasingly benefiting from regenerative medicine approaches.
  • Veterinary medicine offers a unique “One Health” platform to conduct preclinical studies that may translate across species, including humans.
  • While mesenchymal stem/stromal cells (MSCs) derived therapies are already in use for horses, the generation and utilization of equine induced pluripotent stem cells (eqiPSCs) remain underdeveloped.
  • iPSCs possess characteristics of pluripotency — the ability to differentiate into any cell type — making them highly promising for therapeutic and disease modeling applications.

Research Objective

  • To systematically compare the reprogramming potential of equine cells derived from three developmental stages: prenatal (embryonic mesenchymal stem cells, eMSCs), perinatal (cord blood MSCs, CB-MSCs), and adult (articular chondrocytes, ACs).
  • To evaluate two distinct viral reprogramming methods (retroviral and lentiviral) and varying culture conditions affecting iPSC generation.
  • To analyze gene expression and cellular characteristics at multiple time points to identify transcriptomic changes during reprogramming.

Methods

  • Cell Sources: Equine cells from three distinct origins:
    • Embryo-derived MSCs (eMSCs) — prenatal stage
    • Cord blood MSCs (CB-MSCs) — perinatal stage
    • Articular chondrocytes (ACs) — adult stage
  • Reprogramming Techniques: Two viral vector systems employed for delivering pluripotency genes:
    • Retroviral vectors
    • Lentiviral vectors
  • Culture Conditions Tested:
    • Serum-containing versus serum-free media
    • Feeder cells presence versus feeder-free culture
    • Use of small molecules (bioactive compounds that can affect reprogramming efficiency) versus no additives
  • Characterization Techniques:
    • Alkaline phosphatase (AP) staining to identify pluripotent cells
    • Quantitative gene expression analysis for pluripotency markers at multiple time points
    • Protein expression analysis to confirm pluripotency
    • Functional tests with embryoid body differentiation to demonstrate capacity to form all three germ layers
    • Karyotyping to assess chromosomal stability of generated eqiPSCs

Results

  • Optimal Reprogramming Conditions:
    • Lentiviral vectors combined with serum-free media and feeder cells provided the most efficient reprogramming environment.
    • The inclusion of small molecules surprisingly had a negative effect on reprogramming efficiency in this context.
  • Cell Source Impact:
    • Cord blood MSCs (CB-MSCs) and adult articular chondrocytes (ACs) were only partially reprogrammed and lacked capacity for successful expansion of pluripotent cells.
    • Embryo-derived MSCs (eMSCs) uniquely generated putative eqiPSCs that satisfied established criteria for pluripotent stem cells at the molecular, cellular, and functional level.
    • eMSCs demonstrated higher baseline proliferation and endogenous expression of pluripotent genes compared to CB-MSCs and ACs, correlating with superior reprogramming success.
    • During reprogramming, eMSCs showed the most significant upregulation of genes associated with pluripotency.

Conclusions and Significance

  • The developmental origin of the starting somatic cells significantly affects reprogramming outcome in horses — prenatal cells have higher reprogramming potential than perinatal or adult cells.
  • This finding supports observations from human and other species but uniquely provides direct comparative data for equine cells from multiple developmental stages.
  • Insights into transcriptomic changes across cell types during reprogramming and the influence of culture conditions can guide the optimization of eqiPSC generation protocols.
  • Though non-integrating transgene-free reprogramming methods are the ultimate aim for clinical applications, establishing putative eqiPSCs through current methods is vital for advancing basic understanding of equine iPSC biology.
  • These advancements will aid in developing regenerative therapies for horses and strengthen veterinary medicine’s role in One Health translational research.

Cite This Article

APA
Barrachina L, Ivanovska A, Eslami Arshaghi T, O'Brien A, Cequier A, Murphy M, Hollinshead F, Rodellar C, Barry F. (2025). Generation of equine induced pluripotent stem cells from cells of embryonic, perinatal and adult tissues. Stem Cell Res Ther, 16(1), 547. https://doi.org/10.1186/s13287-025-04671-1

Publication

Stem cell research & therapy
ISSN: 1757-6512
NlmUniqueID: 101527581
Country: England
Language: English
Volume: 16
Issue: 1
Pages: 547
PII: 547

Researcher Affiliations

Barrachina, Laura
  • Regenerative Medicine Institute (REMEDI), University of Galway, Galway, Ireland.
  • Laboratorio de Genética Bioquímica (LAGENBIO), Universidad de Zaragoza; Instituto Agroalimentario de Aragón (IA2), Universidad de Zaragoza-CITA; Instituto de Investigación Sanitaria de Aragón (IIS), Universidad de Zaragoza, Zaragoza, Spain.
Ivanovska, Ana
  • Regenerative Medicine Institute (REMEDI), University of Galway, Galway, Ireland.
Eslami Arshaghi, Tarlan
  • Regenerative Medicine Institute (REMEDI), University of Galway, Galway, Ireland.
O'Brien, Aisling
  • Regenerative Medicine Institute (REMEDI), University of Galway, Galway, Ireland.
Cequier, Alina
  • Laboratorio de Genética Bioquímica (LAGENBIO), Universidad de Zaragoza; Instituto Agroalimentario de Aragón (IA2), Universidad de Zaragoza-CITA; Instituto de Investigación Sanitaria de Aragón (IIS), Universidad de Zaragoza, Zaragoza, Spain.
Murphy, Mary
  • Regenerative Medicine Institute (REMEDI), University of Galway, Galway, Ireland.
Hollinshead, Fiona
  • Animal Reproduction and Biotechnology Laboratory (ARBL), Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, USA.
Rodellar, Clementina
  • Laboratorio de Genética Bioquímica (LAGENBIO), Universidad de Zaragoza; Instituto Agroalimentario de Aragón (IA2), Universidad de Zaragoza-CITA; Instituto de Investigación Sanitaria de Aragón (IIS), Universidad de Zaragoza, Zaragoza, Spain.
Barry, Frank
  • Regenerative Medicine Institute (REMEDI), University of Galway, Galway, Ireland. frank.barry@universityofgalway.ie.

MeSH Terms

  • Animals
  • Horses
  • Induced Pluripotent Stem Cells / cytology
  • Induced Pluripotent Stem Cells / metabolism
  • Mesenchymal Stem Cells / cytology
  • Mesenchymal Stem Cells / metabolism
  • Cellular Reprogramming
  • Cell Differentiation
  • Cells, Cultured

Grant Funding

  • 101026825 / European Union's Horizon 2020, Marie Sklodowska-Curie Actions
  • PID2020-116352GB-I00 / Ministerio de Ciencia e Innovación (Spain)

Conflict of Interest Statement

Declarations. Ethics approval and consent to participate: Equine eMSCs were isolated at Colorado State University (Colorado, US) under ethics approval of the Institutional Animal Care and Use Committee (title: “Production of equine fetally-derived mesenchymal stem cells and isolation and characterization of their extracellular vesicles”; approval number: 4443; approval date: 17 April 2023). Equine cord blood was obtained under informed owner consent at Irish stud farms, and CB-MSCs were isolated at University of Galway (Galway, Ireland). Ethical approval was not required because the blood was collected from peripartum waste material by non-invasive means for the mare or the foal. Equine BM-MSCs were obtained at the University of Zaragoza (Zaragoza, Spain) under ethics approval of the in-house Advisory Ethics Committee for Animal Research (title: “Optimización del uso de MSCs alogénicas en el tratamiento de patologías articulares equinas: equilibrio inmunomodulación-inmunogenicidad” [“Optimizing the use of allogenic MSCs for treating equine joint pathologies: immunomodulation-immunogenicity balance”]; approval number: PI 15/16; approval date: 22 June 2021). Equine ACs were obtained post mortem at the University of Liverpool (UK) from healthy joints of animals euthanized for reasons unrelated to this study, thus ethics approval was not required but informed owner’s consent was obtained. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

References

This article includes 63 references
  1. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126(4):663–76.
    doi: 10.1016/j.cell.2006.07.024pubmed: 16904174google scholar: lookup
  2. Avior Y, Sagi I, Benvenisty N. Pluripotent stem cells in disease modelling and drug discovery. Nat Rev Mol Cell Biol 2016;17(3):170–82.
    doi: 10.1038/nrm.2015.27pubmed: 26818440google scholar: lookup
  3. Barrachina L, Arshaghi TE, O’Brien A, Ivanovska A, Barry F. Induced pluripotent stem cells in companion animals: how can we move the field forward?. Front Vet Sci 2023;10:1176772.
    doi: 10.3389/fvets.2023.1176772pmc: PMC10168294pubmed: 37180067google scholar: lookup
  4. Committee on Agriculture and Rural, Development EP. REPORT on responsible ownership and care of equidae. 2017.
  5. Ribitsch I, Baptista PM, Lange-Consiglio A, Melotti L, Patruno M, Jenner F. Large animal models in regenerative medicine and tissue engineering: to do or not to do. Front Bioeng Biotechnol 2020;8:972.
    doi: 10.3389/fbioe.2020.00972pmc: PMC7438731pubmed: 32903631google scholar: lookup
  6. Kobold S, Bultjer N, Stacey G, Mueller SC, Kurtz A, Mah N. History and current status of clinical studies using human pluripotent stem cells. Stem Cell Rep 2023;18(8):1592–8.
    doi: 10.1016/j.stemcr.2023.03.005pmc: PMC10444540pubmed: 37028422google scholar: lookup
  7. Peng J, Zhang WJ, Zhang Q, Su YH, Tang LP. The dynamics of chromatin States mediated by epigenetic modifications during somatic cell reprogramming. Front Cell Dev Biol 2023;11:1097780.
    doi: 10.3389/fcell.2023.1097780pmc: PMC9884706pubmed: 36727112google scholar: lookup
  8. David L, Polo JM. Phases of reprogramming. Stem Cell Res 2014;12(3):754–61.
    doi: 10.1016/j.scr.2014.03.007pubmed: 24735951google scholar: lookup
  9. Yu L, Wei Y, Sun HX, Mahdi AK, Pinzon Arteaga CA, Sakurai M. Derivation of intermediate pluripotent stem cells amenable to primordial germ cell specification. Cell Stem Cell 2021;28(3):550–e6712.
    doi: 10.1016/j.stem.2020.11.003pubmed: 33271070google scholar: lookup
  10. Zhang J, Zhao L, Fu Y, Liu F, Wang Z, Li Y. Reprogramming efficiency and pluripotency of mule iPSCs over its parents. Biol Reprod 2023;108(6):887–901.
    doi: 10.1093/biolre/ioad041pmc: PMC10266948pubmed: 37040346google scholar: lookup
  11. Spinelli V, Guillot PV, De Coppi P. Induced pluripotent stem (iPS) cells from human fetal stem cells (hFSCs). Organogenesis 2013;9(2):101–10.
    doi: 10.4161/org.25197pmc: PMC3812283pubmed: 23823661google scholar: lookup
  12. Questa M, Moshref M, Jimenez RJ, Lopez-Cervantes V, Crawford CK, Settles ML. Chromatin accessibility in canine stromal cells and its implications for canine somatic cell reprogramming. Stem Cells Transl Med 2020;10(3):441–54.
    doi: 10.1002/sctm.20-0278pmc: PMC7900587pubmed: 33210453google scholar: lookup
  13. Eminli S, Foudi A, Stadtfeld M, Maherali N, Ahfeldt T, Mostoslavsky G. Differentiation stage determines potential of hematopoietic cells for reprogramming into induced pluripotent stem cells. Nat Genet 2009;41(9):968–76.
    doi: 10.1038/ng.428pmc: PMC3987895pubmed: 19668214google scholar: lookup
  14. Pessôa LVF, Pires PRL, Del Collado M, Pieri NCG, Recchia K, Souza AF. Generation and MiRNA characterization of equine induced pluripotent stem cells derived from fetal and adult multipotent tissues. Stem Cells Int 2019;2019:1393791.
    doi: 10.1155/2019/1393791pmc: PMC6525926pubmed: 31191664google scholar: lookup
  15. Whitworth DJ, Ovchinnikov DA, Sun J, Fortuna PR, Wolvetang EJ. Generation and characterization of leukemia inhibitory factor-dependent equine induced pluripotent stem cells from adult dermal fibroblasts. Stem Cells Dev 2014;23(13):1515–23.
    doi: 10.1089/scd.2013.0461pmc: PMC4066230pubmed: 24555755google scholar: lookup
  16. Tasma Z, Hou W, Damani T, Seddon K, Kang M, Ge Y. Production of extracellular vesicles from equine embryo-derived mesenchymal stromal cells. Reproduction 2022;164(4):143–54.
    doi: 10.1530/rep-22-0215pubmed: 35938796google scholar: lookup
  17. Merlo B, Teti G, Lanci A, Burk J, Mazzotti E, Falconi M. Comparison between adult and foetal adnexa derived equine post-natal mesenchymal stem cells. BMC Vet Res 2019;15(1):277.
    doi: 10.1186/s12917-019-2023-5pmc: PMC6679462pubmed: 31375144google scholar: lookup
  18. Van Loon VJ, Scheffer CJ, Genn HJ, Hoogendoorn AC, Greve JW. Clinical follow-up of horses treated with allogeneic equine mesenchymal stem cells derived from umbilical cord blood for different tendon and ligament disorders. Vet Q 2014;34(2):92–7.
    doi: 10.1080/01652176.2014.949390pubmed: 25072527google scholar: lookup
  19. MacDonald ES, Barrett JG. The potential of mesenchymal stem cells to treat systemic inflammation in horses. Front Vet Sci 2019;6:507.
    doi: 10.3389/fvets.2019.00507pmc: PMC6985200pubmed: 32039250google scholar: lookup
  20. Rim YA, Nam Y, Ju JH. Application of cord blood and cord blood-Derived induced pluripotent stem cells for cartilage regeneration. Cell Transpl 2019;28(5):529–37.
    doi: 10.1177/0963689718794864pmc: PMC7103603pubmed: 30251563google scholar: lookup
  21. Guzzo RM, Scanlon V, Sanjay A, Xu RH, Drissi H. Establishment of human cell type-specific iPS cells with enhanced chondrogenic potential. Stem Cell Rev Rep 2014;10(6):820–9.
    doi: 10.1007/s12015-014-9538-8pubmed: 24958240google scholar: lookup
  22. Bavin EP, Smith O, Baird AE, Smith LC, Guest DJ. Equine induced pluripotent stem cells have a reduced tendon differentiation capacity compared to embryonic stem cells. Front Vet Sci 2015;2:55.
    doi: 10.3389/fvets.2015.00055pmc: PMC4672282pubmed: 26664982google scholar: lookup
  23. Quattrocelli M, Giacomazzi G, Broeckx SY, Ceelen L, Bolca S, Spaas JH. Equine-Induced pluripotent stem cells retain lineage commitment toward myogenic and chondrogenic fates. Stem Cell Rep 2016;6(1):55–63.
    doi: 10.1016/j.stemcr.2015.12.005pmc: PMC4719186pubmed: 26771353google scholar: lookup
  24. Koch TG, Heerkens T, Thomsen PD, Betts DH. Isolation of mesenchymal stem cells from equine umbilical cord blood. BMC Biotechnol 2007;7:26.
    doi: 10.1186/1472-6750-7-26pmc: PMC1904213pubmed: 17537254google scholar: lookup
  25. Cequier A, Romero A, Vázquez FJ, Vitoria A, Bernad E, Fuente S. Equine mesenchymal stem cells influence the proliferative response of lymphocytes: effect of Inflammation, differentiation and MHC-Compatibility. Anim (Basel) 2022;12(8).
    pmc: PMC9031781pubmed: 35454231doi: 10.3390/ani12080984google scholar: lookup
  26. Peffers MJ, Milner PI, Tew SR, Clegg PD. Regulation of SOX9 in normal and Osteoarthritic equine articular chondrocytes by hyperosmotic loading. Osteoarthritis Cartilage 2010;18(11):1502–8.
    doi: 10.1016/j.joca.2010.08.011pmc: PMC3078327pubmed: 20800688google scholar: lookup
  27. Nagy K, Sung HK, Zhang P, Laflamme S, Vincent P, Agha-Mohammadi S. Induced pluripotent stem cell lines derived from equine fibroblasts. Stem Cell Rev Rep 2011;7(3):693–702.
    doi: 10.1007/s12015-011-9239-5pmc: PMC3137777pubmed: 21347602google scholar: lookup
  28. Shimada H, Nakada A, Hashimoto Y, Shigeno K, Shionoya Y, Nakamura T. Generation of canine induced pluripotent stem cells by retroviral transduction and chemical inhibitors. Mol Reprod Dev 2010;77(1):2.
    doi: 10.1002/mrd.21117pubmed: 19890968google scholar: lookup
  29. Xu M, Stattin EL, Murphy M, Barry F. Generation of induced pluripotent stem cells (ARO-iPSC1-11) from a patient with autosomal recessive osteopetrosis harboring the c.212 + 1G > T mutation in SNX10 gene. Stem Cell Res 2017;24:51–4.
    doi: 10.1016/j.scr.2017.07.024pubmed: 29034896google scholar: lookup
  30. Poon MW, He J, Fang X, Zhang Z, Wang W, Wang J. Human ocular epithelial cells endogenously expressing SOX2 and OCT4 yield high efficiency of pluripotency reprogramming.. PLoS ONE 2015;10(7):e0131288.
    doi: 10.1371/journal.pone.0131288pmc: PMC4489496pubmed: 26131692google scholar: lookup
  31. Barrachina L, Remacha AR, Romero A, Vázquez FJ, Albareda J, Prades M. Priming equine bone Marrow-Derived mesenchymal stem cells with Proinflammatory cytokines: implications in Immunomodulation-Immunogenicity Balance, cell Viability, and differentiation potential.. Stem Cells Dev 2017;26(1):15–24.
    doi: 10.1089/scd.2016.0209pubmed: 27712399google scholar: lookup
  32. de Castro RVG, Pieri NCG, Fantinato Neto P, Grizendi BM, Dória RGS, Meirelles FV. In vitro induction of pluripotency from equine fibroblasts in 20% or 5% oxygen.. Stem Cells Int 2020;2020:8814989.
    doi: 10.1155/2020/8814989pmc: PMC7785345pubmed: 33456472google scholar: lookup
  33. Hauser S, Schuster S, Theurer Y, Synofzik M, Schöls L. Generation of optic atrophy 1 patient-derived induced pluripotent stem cells (iPS-OPA1-BEHR) for disease modeling of complex optic atrophy syndromes (Behr syndrome).. Stem Cell Res 2016;17(2):426–9.
    doi: 10.1016/j.scr.2016.09.012pubmed: 27879217google scholar: lookup
  34. Sharma R, Livesey MR, Wyllie DJ, Proudfoot C, Whitelaw CB, Hay DC. Generation of functional neurons from feeder-free, keratinocyte-derived equine induced pluripotent stem cells.. Stem Cells Dev 2014;23(13):1524–34.
    doi: 10.1089/scd.2013.0565pubmed: 24548115google scholar: lookup
  35. Moro LN, Amin G, Furmento V, Waisman A, Garate X, Neiman G. MicroRNA characterization in equine induced pluripotent stem cells.. PLoS ONE 2018;13(12):e0207074.
    doi: 10.1371/journal.pone.0207074pmc: PMC6277106pubmed: 30507934google scholar: lookup
  36. Petersen GF, Hilbert B, Trope G, Kalle W, Strappe P. Efficient transduction of equine adipose-derived mesenchymal stem cells by VSV-G pseudotyped lentiviral vectors.. Res Vet Sci 2014;97(3):616–22.
    doi: 10.1016/j.rvsc.2014.09.004pubmed: 25443656google scholar: lookup
  37. Breton A, Sharma R, Diaz AC, Parham AG, Graham A, Neil C. Derivation and characterization of induced pluripotent stem cells from equine fibroblasts.. Stem Cells Dev 2013;22(4):611–21.
    doi: 10.1089/scd.2012.0052pmc: PMC3564467pubmed: 22897112google scholar: lookup
  38. Baird A, Barsby T, Guest DJ. Derivation of canine induced pluripotent stem cells.. Reprod Domest Anim 2015;50(4):669–76.
    doi: 10.1111/rda.12562pubmed: 26074059google scholar: lookup
  39. Guo L, Lin L, Wang X, Gao M, Cao S, Mai Y. Resolving cell fate decisions during somatic cell reprogramming by Single-Cell RNA-Seq.. Mol Cell 2019;73(4):815–e297.
    doi: 10.1016/j.molcel.2019.01.042pubmed: 30772174google scholar: lookup
  40. Harman RM, Patel RS, Fan JC, Park JE, Rosenberg BR, Van de Walle GR. Single-cell RNA sequencing of equine mesenchymal stromal cells from primary donor-matched tissue sources reveals functional heterogeneity in immune modulation and cell motility.. Stem Cell Res Ther 2020;11(1):524.
    doi: 10.1186/s13287-020-02043-5pmc: PMC7716481pubmed: 33276815google scholar: lookup
  41. Bressan FF, Bassanezze V, de Figueiredo Pessôa LV, Sacramento CB, Malta TM, Kashima S. Generation of induced pluripotent stem cells from large domestic animals.. Stem Cell Res Ther 2020;11(1):247.
    doi: 10.1186/s13287-020-01716-5pmc: PMC7318412pubmed: 32586372google scholar: lookup
  42. Baird A, Dominguez Falcon N, Saeed A, Guest DJ. Biocompatible Three-Dimensional printed thermoplastic scaffold for osteoblast differentiation of equine induced pluripotent stem cells.. Tissue Eng Part C Methods 2019;25(5):253–61.
    doi: 10.1089/ten.TEC.2018.0343pubmed: 30834821google scholar: lookup
  43. Yang F, Richardson DW. Comparative analysis of tenogenic gene expression in Tenocyte-Derived induced pluripotent stem cells and bone Marrow-Derived mesenchymal stem cells in response to biochemical and Biomechanical stimuli.. Stem Cells Int 2021;2021:8835576.
    doi: 10.1155/2021/8835576pmc: PMC7825360pubmed: 33510795google scholar: lookup
  44. Chung MJ, Park S, Son JY, Lee JY, Yun HH, Lee EJ. Differentiation of equine induced pluripotent stem cells into mesenchymal lineage for therapeutic use.. Cell Cycle 2019;18(21):2954–71.
    doi: 10.1080/15384101.2019.1664224pmc: PMC6791704pubmed: 31505996google scholar: lookup
  45. Chen J, Liu H, Liu J, Qi J, Wei B, Yang J. H3K9 methylation is a barrier during somatic cell reprogramming into iPSCs.. Nat Genet 2013;45(1):34–42.
    doi: 10.1038/ng.2491pubmed: 23202127google scholar: lookup
  46. Wu X, Dao Thi VL, Huang Y, Billerbeck E, Saha D, Hoffmann HH. Intrinsic Immunity Shapes Viral Resistance of Stem Cells.. Cell 2018;172(3):423 – 38.e25.
    pmc: PMC5786493pubmed: 29249360doi: 10.1016/j.cell.2017.11.018google scholar: lookup
  47. Haas S, Trumpp A. An intrinsic interferon program protects stem cells from viral infection.. Dev Cell 2018;44(3):279–80.
    doi: 10.1016/j.devcel.2018.01.013pubmed: 29408233google scholar: lookup
  48. Ruiz S, Panopoulos AD, Herrerías A, Bissig K-D, Lutz M, Berggren WT. A high proliferation rate is required for cell reprogramming and maintenance of human embryonic stem cell identity.. Curr Biol 2011;21(1):45–52.
    doi: 10.1016/j.cub.2010.11.049pmc: PMC3034649pubmed: 21167714google scholar: lookup
  49. Tobias IC, Kao MC, Parmentier T, Hunter H, LaMarre J, Betts DH. Targeted expression profiling reveals distinct stages of early canine fibroblast reprogramming are regulated by 2-oxoglutarate hydroxylases.. Stem Cell Res Ther 2020;11(1):528.
    doi: 10.1186/s13287-020-02047-1pmc: PMC7725121pubmed: 33298190google scholar: lookup
  50. Nantavisai S, Rodprasert W, Pathanachai K, Wikran P, Kitcharoenthaworn P, Smithiwong S. Simvastatin enhances proliferation and pluripotent gene expression by canine bone marrow-derived mesenchymal stem cells (cBM-MSCs) in vitro.. Heliyon 2019;5(10):e02663.
    doi: 10.1016/j.heliyon.2019.e02663pmc: PMC6820287pubmed: 31687506google scholar: lookup
  51. Haridhasapavalan KK, Raina K, Dey C, Adhikari P, Thummer RP. An insight into reprogramming barriers to iPSC generation.. Stem Cell Rev Rep 2020;16(1):56–81.
    doi: 10.1007/s12015-019-09931-1pubmed: 31758374google scholar: lookup
  52. Gordeeva O. TGFβ Family Signaling Pathways in Pluripotent and Teratocarcinoma Stem Cells’ Fate Decisions: Balancing Between Self-Renewal, Differentiation, and Cancer.. Cells 2019;8(12).
    pmc: PMC6953027pubmed: 31771212doi: 10.3390/cells8121500google scholar: lookup
  53. Li Z, Ge W, Li Y, Zhang Y, Zhao X, Hu J. Valproic acid enhance reprogramming of bactrian camel cells through promoting the expression of endogenous gene c-Myc and the process of angiogenesis.. Int J Stem Cells 2021;14(2):191–202.
    doi: 10.15283/ijsc20213pmc: PMC8138656pubmed: 33632993google scholar: lookup
  54. Mullen AC, Wrana JL. TGF-β family signaling in embryonic and somatic Stem-Cell renewal and differentiation.. Cold Spring Harb Perspect Biol 2017;9(7).
    pmc: PMC5495062pubmed: 28108485doi: 10.1101/cshperspect.a022186google scholar: lookup
  55. Smith KP, Luong MX, Stein GS. Pluripotency: toward a gold standard for human ES and iPS cells.. J Cell Physiol 2009;220(1):21–9.
    doi: 10.1002/jcp.21681pubmed: 19326392google scholar: lookup
  56. Ezashi T, Yuan Y, Roberts RM. Pluripotent stem cells from domesticated mammals.. Annu Rev Anim Biosci 2016;4:223–53.
    doi: 10.1146/annurev-animal-021815-111202pubmed: 26566158google scholar: lookup
  57. Paterson YZ, Kafarnik C, Guest DJ. Characterization of companion animal pluripotent stem cells.. Cytometry A 2018;93(1):137–48.
    doi: 10.1002/cyto.a.23163pubmed: 28678404google scholar: lookup
  58. Su Y, Zhu J, Salman S, Tang Y. Induced pluripotent stem cells from farm animals.. J Anim Sci 2020.
    doi: 10.1093/jas/skaa343pmc: PMC7660146pubmed: 33098420google scholar: lookup
  59. Lee EM, Kim AY, Lee EJ, Park JK, Park SI, Cho SG. Generation of Equine-Induced pluripotent stem cells and analysis of their therapeutic potential for muscle injuries.. Cell Transpl 2016;25(11):2003–16.
    doi: 10.3727/096368916x691691pubmed: 27226077google scholar: lookup
  60. Menon DV, Bhaskar S, Sheshadri P, Joshi CG, Patel D, Kumar A. Positioning canine induced pluripotent stem cells (iPSCs) in the reprogramming landscape of naïve or primed state in comparison to mouse and human iPSCs.. Life Sci 2021;264:118701.
    doi: 10.1016/j.lfs.2020.118701pubmed: 33130086google scholar: lookup
  61. Golipour A, David L, Liu Y, Jayakumaran G, Hirsch CL, Trcka D. A late transition in somatic cell reprogramming requires regulators distinct from the pluripotency network.. Cell Stem Cell 2012;11(6):769–82.
    doi: 10.1016/j.stem.2012.11.008pubmed: 23217423google scholar: lookup
  62. Hotta A, Ellis J. Retroviral vector Silencing during iPS cell induction: an epigenetic beacon that signals distinct pluripotent States.. J Cell Biochem 2008;105(4):940–8.
    doi: 10.1002/jcb.21912pubmed: 18773452google scholar: lookup
  63. Palomino Lago E, Jelbert ER, Baird A, Lam PY, Guest DJ. Equine induced pluripotent stem cells are responsive to inflammatory cytokines before and after differentiation into musculoskeletal cell types.. Vitro Cell Dev Biol Anim 2023;59(7):514–27.
    doi: 10.1007/s11626-023-00800-3pmc: PMC10520172pubmed: 37582999google scholar: lookup

Citations

This article has been cited 0 times.
Subscribe to our newsletter
Join 100,191 horse owners like you who receive our email updates on horse health and nutrition.